Company intelligence / Profile preview

Sansure Biotech

Changsha, Hunan, Chinasansureglobal.com ↗

Ownership: Private
Development stage: Commercial

Overview

Sansure Biotech has commercialized over 1,000 products and more than 2,200 high-quality testing services. Its molecular diagnostic kits are widely used in hospitals and laboratories across more than 160 countries. The company’s COVID-era nucleic acid testing solutions became market leaders in Europe and Asia. Financially robust with $600 million revenue in 2023 and strong R&D investment driving innovation

Therapeutic areas: OncologyInfectious Diseases
Modalities: Molecular diagnosticsPCR-based diagnosticsImmunoassay solution
Industry: Molecular Diagnostics

Partnerships

Notable contracts with governmental health agencies internationally for pandemic response suppliesIFC investment partnershipcollaborations with academic institutions for research

Beyond the preview

Go deeper on Sansure Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sansure Biotech.

Explore the full profile